首页 工具
登录
购物车

搜索结果

Search Results for " pi3k-in-10 "

如果没找到您满意的产品或者您对产品有其他要求,可以联系我们专业顾问为您提供针对性的合理建议。     QQ咨询       网站留言咨询

提交您的定制咨询

点击图片重新获取验证码
Cat. No. Product Name Target Signaling Pathways
T12456 PI3K-IN-10

PI3K PI3K/Akt/mTOR signaling
PI3K-IN-10 is a potent inhibitor of pan-PI3K .
T64219 PI3K/mTOR Inhibitor-6

PI3K/mTOR Inhibitor-6 (Compound 19c) 是一种有效的 PI3K/mTOR 双重抑制剂,在人工胃液中的稳定性比 gedatolisib 更高。10 μM 的 PI3K/mTOR Inhibitor-6 能够明显抑制 PI3K/Akt/mTOR 信号通路。PI3K/mTOR Inhibitor-6 对癌症疾病表现出研究潜力。
T62409 PI3K-IN-23

PI3K-IN-23 是一种 (E)-9-oxooctadec-10-en-12-ynoic acid 类似物,能够促进葡萄糖摄取 (EC50: 7.00 μM)。
T64041 PI3K/mTOR Inhibitor-7

PI3K/mTOR Inhibitor-7 是有效的 PI3K/mTOR 双重抑制剂。PI3K/mTOR Inhibitor-7 的作用比 gedatolisib 高 4.7 倍,他们的 IC50 值分别为 1.4 μM 和 0.3 μM。10 μM 的 PI3K/mTOR Inhibitor-7 能够明显抑制 PI3K/Akt/mTOR 信号通路。PI3K/mTOR Inhibitor-7 对癌症疾病表现出研究潜力。
T63211 AKT-IN-10

AKT-IN-10 是有效的 AKT 抑制剂,对乳腺癌和前列腺癌表现出研究潜力。其中蛋白激酶 B (PKB,也称为 AKT) 是细胞中 PI3K/AKT/mTOR 信号传导的核心,其功能对细胞生长、存活、分化和代谢很重要。
T36421 Immuno-Oncology Screening Library

The Immuno-Oncology Screening Library consists of 2 plates and contains more than 90 cancer and immunology-associated compounds in a 96-well Matrix tube rack format as 10 mM stock solutions in DMSO. This library includes a variety of immuno-oncology target modulators, including but not limited to, adenosine, CCR, CXCR, and TLR agonists and antagonists, BTK, PI3K, VEGFR, and BRAF inhibitors, PD-1/PDL-1 interaction inhibitors, and HDAC inhibitors. Please review the product insert for a full list ...
T79449 Antileishmanial agent-19

Parasite Microbiology/Virology
Antileishmanial agent-19 (Compound F27)是一种有效的抗利什曼病试剂,其对L. donovani promastigotes的IC50值为3.39 μM。该化合物能够抑制L. donovani promastigotes中的脯氨酰-tRNA合成酶,并干预宿主PI3K/Akt/CREB轴,从而抑制IL-10的分泌。此外,Antileishmanial agent-19能诱导L. donovani promastigotes自噬介导的细胞凋亡(apoptosis)过程,并在感染的动物体内显著减少寄生虫负担。
T78871 PLM-101

PLM-101是一种口服抗癌剂,针对FLT3和RET具有选择性抑制作用,有效抑制急性髓系白血病(AML)细胞。通过抑制RET,PLM-101促使FLT3的自噬降解,并且通过抑制PI3K和Ras/ERK信号通路来发挥其抗白血病的活性。在小鼠MV4-11侧翼异种移植模型中,PLM-101以口服剂量3及10 mg/kg显示出抗肿瘤效果,并且在同种异种移植小鼠模型中,剂量为40 mg/kg(口服)亦展现出明显的抗肿瘤功效。
T36308 PF-06843195

PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts. The Kis of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy[1]. PF-06843195 inhibits the breast cancer cell lines MCF7 and T47D proliferation with IC50s of 62 nM and 32 nM, respectively[1].PF-06843195 inhibits pAKT (T308) in MCF7 and T47D cells w...

化合物

PI3K-IN-10
Cat.No: T12456
Synonym:
Target: PI3K
PI3K/mTOR Inhibitor-6
Cat.No: T64219
Synonym:
Target:
PI3K-IN-23
Cat.No: T62409
Synonym:
Target:
PI3K/mTOR Inhibitor-7
Cat.No: T64041
Synonym:
Target:
AKT-IN-10
Cat.No: T63211
Synonym:
Target:
Immuno-Oncology Screening Library
Cat.No: T36421
Synonym:
Target:
Antileishmanial agent-19
Cat.No: T79449
Synonym:
Target: Parasite
PLM-101
Cat.No: T78871
Synonym:
Target:
PF-06843195
Cat.No: T36308
Synonym:
Target:
TargetMol Loading
联系我们
400-820-0310

上海市静安区江场三路238号8楼